M 002
Alternative Names: AAV-S1S3; M-002Latest Information Update: 28 Feb 2025
At a glance
- Originator M6P Therapeutics
- Class 3-ring heterocyclic compounds; Amides; Gene therapies; Small molecules
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Metabolic bone diseases
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Metabolic bone diseases in USA (Parenteral)
- 09 Feb 2023 M6P Therapeutics plans to file IND in Metabolic bone disorders by Q3 2024 (M6P Therapeutics website, February 2023)
- 17 May 2021 Pharmacodynamics data from a preclinical studies in Mucolipidosis type II ([metabolic bone diseases) presented at the American Society of Gene & Cell Therapy (ASGCT-2021)